Canada Markets open in 4 hrs 33 mins

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2367-0.0153 (-6.07%)
At close: 03:59PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

    701 subjects dosed to dateInitiating enrollment activities in Turkey as part of its clinical diversification plans to support global regulatory approvals On-track to complete enrollment in Q1-2022 and FDA submission thereafterCommencing regulatory package activities for submission to international regulatory authorities for drug approvals TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sci

  • GlobeNewswire

    Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

    IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psilocybin pharmaceutical de

  • GlobeNewswire

    Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

    Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, wishes to clarify certain disclosures in its press release titl